PRAX Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. (PRAX) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $3.65 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.7% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance.
Sector
Healthcare
Industry
Biotechnology